No Data
3sbio (01530.HK): Shenyang 3sbio and guangdong hec technology holding reached a cooperation on sulfonamic acid clifene.
Gelonghui November 25th | 3sbio (01530.HK) announced that its subsidiary Shenyang 3sbio Pharmaceutical Co., Ltd. has reached a cooperation agreement with Guangdong Hec CJ Pharm Co., Ltd. and its subsidiary Yichang Hec CJ Pharm Co., Ltd. on the commercialization of specific indications of Benzoate Crizotinib. According to the agreement, Shenyang 3sbio will obtain the exclusive commercialization rights of Crizotinib specific indications under the product portfolio of Guangdong Hec CJ Pharm in mainland China. Shenyang 3sbio will make the initial payment and corresponding R&D and sales milestone payments to Guangdong Hec CJ Pharm as agreed in the agreement. Guangdong Hec CJ Pharm will continue to be responsible for the Crizotinib
Why Investors Shouldn't Be Surprised By Guangdong HEC Technology Holding Co., Ltd's (SHSE:600673) P/S
Guangdong Hec Technology Holding (01558): Guangdong Hec Pharmaceutical and Apollo company have reached an authorization licensing agreement on the development and commercialization of HEC88473 project.
hec cj pharm (01558) and the offeror guangdong hec technology holding pharmaceutical limited jointly announced the 2024 ...
We Think That There Are More Issues For Guangdong HEC Technology Holding (SHSE:600673) Than Just Sluggish Earnings
Dongyangguang: Dongyangguang Third Quarter Report 2024
Dongyangyang Third Quarter Report 2024
Should We Be Cautious About Guangdong HEC Technology Holding Co., Ltd's (SHSE:600673) ROE Of 2.8%?
